Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

29 Oct 2016 Reuters Investment Profile 12 $20.00

Wright Investors Service Comprehensive Report for Basilea Pharmaceutica Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

26 Sep 2016 Wright Reports 65 $75.00

BASILEA PHARMACEUTICA - MOVING ON UP

Basilea has made a solid start to the first half of 2016, with anti-microbial agents Cresemba and Zevtera continuing their re...

30 Aug 2016 Edison Investment Research 7 $10.00

BSLN.S - Event Transcript of Basilea Pharmaceutica AG conference call, Aug. 15, 2016 / 10:00AM ET

Edited Event Transcript of BSLN.S conference call, Aug. 15, 2016 / 10:00AM ET Boston, Aug 19, 2016 (Thomson StreetEvent...

15 Aug 2016 Thomson Reuters StreetEvents 11 $75.00

Basilea Pharmaceutica AG: Upgraded to Average

11 Aug 2016 Sadif Analytics Prime 3 $10.00

Is Basilea Pharmaceutica AG Share Price Sustainable?

27 Jun 2016 Sadif Analytics Prime 12 $25.00

Basilea Pharmaceutica AG (BSLN) - Financial Analysis Review

Basilea Pharmaceutica AG (BSLN) - Financial Analysis Review Summary Basilea Pharmaceutica AG (Basilea) is a pharmaceutical co...

17 Jun 2016 GlobalData 49 $300.00

Basilea Pharmaceutica AG: Downgraded to Risky

17 May 2016 Sadif Analytics Prime 3 $10.00

BASILEA PHARMACEUTICA - ZEVTERA US DEVELOPMENT FULL STEAM AHEAD

Basilea has announced that BARDA, a division of the US Department of Health & Human Services Office, has awarded a contract o...

22 Apr 2016 Edison Investment Research 5 $10.00

BASILEA PHARMACEUTICA - RIDING THE CREST OF THE NOVEL ANTIMICROBIAL WAVE

Basilea is one of the few standalone European companies focused on developing novel antimicrobial drugs. It has two approved ...

23 Mar 2016 Edison Investment Research 16 $10.00